NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines
The National Health Commission (NHC) has released a notification including Simcere Pharmaceutical Group’s (HKG: 2096)...
Junshi Biosciences
Junshi Biosciences Reports 2022 Preliminary Earnings with Revenue Decline
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has released its 2022 preliminary earnings estimate, indicating...
Junshi Biosciences’ PCSK9 Inhibitor Ongericimab Meets Phase III Endpoints
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that two randomized, double-blind, placebo-controlled, multi-center...
Junshi Biosciences’ PD-1 Inhibitor Tuoyi Shows Promise in Phase III TNBC Study
Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced significant progress in the Phase...
Junshi Biosciences Seeks UK MHRA Approval for PD-1 Inhibitor Tuoyi
Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biotech firm, has announced the submission...
Junshi Biosciences and Coherus Report Positive JUPITER-02 Trial Results for NPC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) and its US partner Coherus BioSciences...
Junshi Biosciences’ COVID-19 Therapy Faces Supply Issues, Partners with Sihuan Pharma
Junshi Biosciences’ (HKG: 1877, SHA: 688180) COVID-19 therapy JT001 (VV116) appears to be facing supply...
JunTop Biosciences’ COVID-19 Therapy Mindewei Priced at RMB 795 per Course
Sichuan’s provincial Healthcare Security Administration bureau has notified that Shanghai JunTop Biosciences Co., Ltd’s COVID-19...
Junshi Biosciences’ JS401 Accepted for Review by China’s NMPA for Hyperlipidemia
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that the National Medical Products Administration...
Junshi Biosciences Partners with Huahai for Production of COVID-19 Drug VV116
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a production and supply agreement between...
Junshi Biosciences’ Neotorch Study Achieves Superiority in Lung Cancer Trial
Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that its randomized, double-blind, placebo-controlled,...
Junshi Biosciences’ COVID-19 Drug JT001 (VV116) Accepted for NMPA Review
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that its oral nucleoside analog drug...
Junshi Biosciences’ CGRP Monoclonal Antibody JS010 Accepted for NMPA Review
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that the clinical trial filing for...
Junshi Biosciences’ JT001 (VV116) Shows Non-Inferiority to Paxlovid in COVID-19 Trial
The results of a Phase III clinical study for China-based Junshi Biosciences’ (HKG: 1877, SHA:...
Junshi Biosciences’ PD-1 Inhibitor Tuoyi Faces FDA Review Delay
Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that they have not received...
Junshi Biosciences Licenses PD-1 Inhibitor Tuoyi to Hikma MENA FZE
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a licensing agreement with UK-headquartered Hikma...
ASH 2022: China Biotechs Showcase Latest Clinical Trial Results
The American Society of Hematology (ASH) 2022 annual meeting, held online and offline in New...
Harbour BioMed Concludes Phase I Study for HBM4003 in Advanced Melanoma
Harbour BioMed (HBM; HKG: 2142), a biotech operating out of the United States, the Netherlands,...
Junshi Biosciences Files for EMA Approval of Tuoyi for Nasopharyngeal and Esophageal Cancers
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that a market approval filing has been...
Double-Crane Pharma Gains NMPA Approval for COVID-19 Drug CX2101A Clinical Trials
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced receiving clinical trial approval from...